“We have clearly demonstrated that the design platform technology for nanoviricides allows development of powerful broad-spectrum antiviral drugs,” said Anil R. Diwan, PhD, President and Chairman of the Company, “We have developed a small chemical ligand that mimics both the mammalian (or a-2,6-) and avian (or a-2,3) forms of the native sialic acid receptor of influenza viruses. We can design a nanoviricide to exhibit several ligands at a single point, and each nanomicelle may exhibit several hundred ligands on its small surface. The ligands are designed to look very much like (mimic) the sialic acid to the influenza viruses, and the high density of the ligands would force the virus to land onto the nanoviricide and get destroyed by the hidden ‘tails’ of the nanomicelle that snap out and merge into the viral surface lipid coat.”
Like "LEGO pieces" you plug-in the nano-micelle and bio-mimetic receptor protein (mimics "host's" cells - target cells of the virus) together to produce the most lethal enemy to a human-killing virus.
The lengthy visit to the hospital will be replaced by a short visit to the clinic:
An individual, feeling sick, goes to a clinic. The individual is diagnosed as being the host to a human-killing virus. The patient is prescribed a Cide for the indicated virus. Trillions of Cide particles quickly start circulating in the host's bloodstream. The virus structures are drawn to the Cide particles, the virus attacks/connects to the Cide micelle via ligands/receptors, the Cide envelopes the virus structure and destroys it. This event happens in the trillions and in a matter of hours. In a matter of hours, after arriving at the clinic sick, the individual is feeling better and he/she has averted a lengthy and financially crushing stay at the hospital.
The mechanism employed by Nanoviricides, Inc. to envelope the virus is patented. There are over 100 countries to approve "first in class" patent applications ~ 4Q 2013.
